<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5779">
  <stage>Registered</stage>
  <submitdate>29/02/2016</submitdate>
  <approvaldate>29/02/2016</approvaldate>
  <nctid>NCT02708576</nctid>
  <trial_identification>
    <studytitle>Phase 1 Study of NGM313 in Healthy Adult Participants</studytitle>
    <scientifictitle>A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>15-0201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - NGM313
Other interventions - Placebo

Experimental: NGM313 - Administration of active NGM313

Placebo Comparator: Placebo - Administration of placebo comparator


Other interventions: NGM313


Other interventions: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute change in weight in kilograms</outcome>
      <timepoint>28 and 84 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in fasting glucose in mmol/L</outcome>
      <timepoint>28 and 84 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  BMI range 27-40 kg/m2, inclusive for the SAD module, and 27-40 kg/m2, inclusive for
             the MAD module;

          -  Normal clinical laboratory evaluations

          -  Normal ECG findings</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Significant history or clinical manifestation of any significant metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, or psychiatric disorder

          -  Uncontrolled hypertension defined as sitting blood pressure systolic &gt; 150 mm/Hg
             and/or diastolic &gt; 90 mm/Hg</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>151</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>NGM Clinical Study Site - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>NGM Biopharmaceuticals, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety and tolerability of NGM313, both single
      dose and multiple doses, in normal healthy overweight and obese adult participants.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02708576</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Que Liu, MD</name>
      <address>NGM Biopharmaceuticals, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>